Nebivolol in Obese and Non-Obese Hypertensive Patients
Article first published online: 11 MAY 2009
© 2009 Wiley Periodicals, Inc.
The Journal of Clinical Hypertension
Volume 11, Issue 6, pages 309–315, June 2009
How to Cite
Manrique, C., Whaley-Connell, A. and Sowers, J. R. (2009), Nebivolol in Obese and Non-Obese Hypertensive Patients. The Journal of Clinical Hypertension, 11: 309–315. doi: 10.1111/j.1751-7176.2009.00119.x
- Issue published online: 9 JUN 2009
- Article first published online: 11 MAY 2009
- Manuscript received December 15, 2008; revised March 20, 2009; accepted March 25, 2009
Use of β-blockers in hypertensive obese patients remains controversial because of concerns about potential influences on weight, lipids, and glucose metabolism. The authors examined a pooled analysis of 3 multicenter randomized placebo-controlled trials. Patients were randomized to placebo or an increasing dose of nebivolol for 12 weeks. Primary outcome was the mean baseline to end point change in trough mean sitting diastolic blood pressure (SiDBP). Secondary outcomes were baseline to end point changes in trough sitting systolic blood pressure (SiSBP); trough standing and peak supine diastolic blood pressure and systolic blood pressure. Nebivolol reduced SiDBP significantly compared with placebo at all doses ≥2.5 mg in obese and non-obese patients. Reductions in SiSBP with nebivolol were higher than controls at all studied doses ≥5 mg in non-obese and ≥2.5 mg in obese patients. These findings and nebivolol’s neutral effects on lipid and carbohydrate metabolism suggest that it is one option for blood pressure control in the moderately obese population.